Anna B. Halpern, MD

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Anna B. Halpern, MD, discusses investigational efforts to utilize ruxolitinib and navitoclax in earlier treatment lines for patients with myelofibrosis.

Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

Anna B. Halpern, MD, discusses symptom control, transfusion independence, and spleen volume findings with the JAK and ACVR1 inhibitor momelotinib vs the JAK inhibitor ruxolitinib and danazol in patients with myelofibrosis with anemia.